Project Grant R34EY037743
Award Date 9/30/25
Completion Date 9/29/27
Dollars Obligated $492K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This Project Grant award for $383,000 from the National Eye Institute (CFDA 93.867 - Vision Research) aims to identify social determinants of health (SDOH) indicators associated with disparities in the diagnosis, management, and prognosis of dry eye disease. The project will leverage electronic health record data from a single-center and multi-center (Sight Outcomes Research Collaborative) datasets to build prognostic models that account for individual and structural barriers to accessing eye...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) supports the development of a novel, noninvasive, and sensitive diagnostic method to measure retinal dysfunction. The $491,466 award will fund research at the University of California, San Francisco (UCSF) from January 1, 2025 to December 31, 2026. The project aims to create a scalable diagnostic tool that can detect the earliest signs of retinal diseases like diabetic retinopathy and retinitis pigmentosa,...
- This Project Grant award from the National Eye Institute's Vision Research program provides funding of $442,750 to the University of California, Davis for a research project titled "Defining a New Model of Evaporative Dry Eye Disease." The project aims to utilize an emerging murine model of evaporative dry eye disease, which is characterized by a dysfunctional tear film lipid layer, to better understand the pathogenesis of this condition and explore potential therapeutic approaches....
- This $348,800 Project Grant was awarded on September 30, 2025 by the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), to N'Waii Inc. in Chicago, Illinois. The grant supports the development of a first-in-class mitochondrially targeted antioxidant drug candidate for the treatment of dry eye disease (DED), a condition affecting 20% of the global adult population. The drug candidate exhibits potent free radical scavenging capabilities and has demonstrated...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $321,904 Project Grant to Proteris Biotech, Inc. through the Vision Research federal grant program (CFDA 93.867). The award, spanning August 1, 2025 to July 31, 2026, will fund the early development of the natural tear protein clusterin (CLU) as a novel approach to treat dry eye disease. The research aims to conduct non-GMP stability analysis of the drug substance and product, as well as perform...
- This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides funding of $294,662 to Proteris Biotech, Inc. to support research on using the protein Clusterin (CLU) to treat ocular surface disease and dry eye. The project aims to determine whether CLU can protect the ocular surface epithelia from damage and also have an anti-inflammatory effect in dry eye disease. Recombinant human CLU will be tested for efficacy in a mouse...
- This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $246,000 to The Regents of the University of California, San Francisco to conduct research on serum components that support corneal health. The goal is to define the combinations of serum factors, such as growth factors, signaling lipids, and vitamins, that can restore healthy corneal function and treat diverse ocular surface disorders. The research aims to improve the clinical use of...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $730,000 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotech firm, to develop an optimized nerve growth factor (NGF) therapy for the treatment of dry eye disease (DED). The funding will support preclinical studies to evaluate the efficacy and mechanism of action of the company's proprietary NGF mutein (HC201) in improving tear film production and corneal...
- The Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) supports the development of an accurate, non-invasive, and automated 24-hour intraocular pressure (IOP) monitoring device. The overarching goal is to create a wearable IOP monitor that can improve the clinical management of glaucoma, the leading cause of irreversible blindness. The $713,964 award will fund research activities over a 5-year period from March 2025 to February 2030 at the University of California,...
- This federal Project Grant award of $1,523,433.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research by the Doheny Eye Institute in Pasadena, California to investigate the mechanobiology of retinal vascular inflammation and degeneration in diabetic retinopathy. The key products and services to be delivered include: Exploring how diabetes-induced stiffening of the retinal capillary basement membrane leads to activation of endothelial cells and inflammation,...